Demonstrating the value of health interventions through transparent and user-friendly health economic models

Health economic evaluation plays an important role in demonstrating value by assessing the costs and outcomes of healthcare interventions and services. At YHEC, we specialise in delivering high-quality and user-friendly health economic models that empower our clients (from industry to the NHS and public health bodies) to make informed decisions and optimise resource allocation.

How can YHEC’s health economics expertise help you?

Our clients often seek our expertise to inform a range of crucial decisions, including:

  • Early-stage development: Providing early economic models (including cost-comparison and simulation models) to explore pricing thresholds, refine clinical trial design, and shape go/no-go decisions.
  • Market access and HTA submissions: Developing robust evidence (such as cost-effectiveness and budget impact models) that meets national and international HTA requirements, while maintaining clarity and usability.
  • Strategic value communication: Creating compelling and data-driven value propositions for payers, policymakers and providers.
  • Service efficiency and redesign: Evaluating the economic and operational impact of new service delivery models, digital tools, or workforce changes in local or national health systems. We also assist local health systems in auditing and understanding the real-world costs and benefits of care pathways.
  • Investment and disinvestment decisions: Equipping decision-makers, such as local commissioners and national health authorities, with transparent analyses to weigh trade-offs and optimise resource use.
  • Long-term impacts: Developing sophisticated population-level models to forecast disease trends, intervention effects, and resource needs over extended time horizons, informing strategic planning and investment decisions for both industry and public health planning.

Why partner with YHEC?

Choosing YHEC for your health economic evaluation needs means partnering with a team that offers:

At YHEC, we tailor all analyses to meet your specific needs, applying methods that are fit for purpose. We consider factors such as data availability, the nuances of the disease area, and the priorities of the target audience. Whether you require a model to support an HTA submission, guide internal strategic planning, or help a health system audit and understand the real-world costs and benefits of care pathways, we design each model to align precisely with your objectives and stakeholder perspectives. This approach ensures the evidence we generate is both relevant and impactful.

To ensure accessibility and usability, we offer flexible user interface options for our economic models. While Microsoft Excel provides a familiar and widely used platform, we also develop models using R-Shiny or Python. This flexibility allows you to choose the interface that best suits your needs and technical capabilities, promoting effective communication and decision support for both technical HTA committees and non-technical decision-makers in a local health trust.

Healthcare systems vary substantially both across the globe and within countries. Our team possesses extensive experience in adapting economic models to account for these variations. Whether your focus is on a global market, a specific country, or a local healthcare setting, we have the expertise to tailor our analyses to the relevant context. This ensures that your economic evidence is applicable to the specific decision-making environment.

We provide clear and comprehensive documentation for our models, ensuring that all assumptions, data sources, and methods are fully explained. We also offer handover training to empower your team to understand and utilise the model effectively. Our communication is always tailored to the target audience, whether it is a technical HTA committee or a non-technical decision-maker. This commitment to transparency, coupled with our established track record of health economic publications, builds trust and confidence in our findings.

Renowned for gold-standard modelling, we are also actively engaged with cutting-edge health economic methods. Recent projects include:

  • Equity-sensitive analyses using distributional cost-effectiveness analysis frameworks to evaluate the fairness, as well as the cost-effectiveness, of innovations.
  • Environmental sustainability assessments that quantify carbon and ecological impacts of interventions and explore their integration in health systems.
  • Model development in R and Python, offering clients greater transparency, reproducibility and flexibility than traditional Excel-based models while ensuring methodological compliance for decision-making processes.

Explore YHEC's recent publications in this area

Peer-reviewed publication

The Cost-Effectiveness of Opicapone Versus Entacapone as Adjuvant Therapy for Levodopa-Treated Individuals With Parkinson’s Disease Experiencing End-of-Dose Motor Fluctuations

YHEC authors: William Green, Jamie Bainbridge
Publication date: September 2025
Journal: Parkinson's Disease

Abstract

BACKGROUND: In levodopa-treated individuals with Parkinson’s disease (PD) and end-of-dose motor fluctuations, the BIPARK-I randomized controlled trial (RCT) demonstrated that opicapone is noninferior to entacapone in reducing OFF-time. Furthermore, the...

Peer-reviewed publication

Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL

YHEC authors: Sam Harper, Daniela Afonso, Karina Watts, Matthew Taylor
Publication date: August 2025
Journal: PharmacoEconomics

Abstract

BACKGROUND AND OBJECTIVE: Health technology assessment (HTA) of haemato-oncology therapies typically requires extrapolation of long-term survival beyond a trial’s follow-up. Health technology assessment agencies must balance caution around uncertainty in...

Peer-reviewed publication

Cost-Effectiveness of the CV-Polypill Strategy Versus Standard Care for Secondary Cardiovascular Prevention in Spain: an Analysis Based on the SECURE Trial

YHEC authors: Amy Dymond, Alissa Looby, Mealing
Publication date: August 2025
Journal: The Lancet Regional Health - Europe

Abstract

BACKGROUND: The SECURE trial (NCT02596126) demonstrated the efficacy of the cardiovascular polypill ("CV-Polypill" - acetyl salicylic acid, atorvastatin and ramipril) in reducing the risk of recurrent major cardiovascular events compared...

Talk to our expert

For more information about health economic evaluation, talk to our expert – Matthew Taylor.

A head and shoulders photo of Matthew Taylor sitting in front of a bookcase in his office.